Institut de Myologie

Institut de Myologie

The Institute of Myology was initiated by a group of leaders, patients and families from the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM) who wished to establish a point of reference where specialised consultations, fundamental and clinical research teams and teaching on muscle and muscle diseases would all be grouped together in a public hospital. The project took shape through AFM’s partnerships with the Assistance Publique-Hôpitaux de Paris (AP-HP), National Institute of Health and Medical Research (Institut National pour la Santé et la Recherche Médicale, Inserm), the Université Paris VI and the  Nuclear Energy Commission  (Commissariat à l’Energie Atomique, CEA).


To reach this objective, the Institute of Myology has set itself the following missions:to bring research, clinical activities and teaching together in the same placeto gather performing means of investigation for diagnosis and careto create a centre of expertise and a point of reference on muscle and muscle diseasesto set up coordinated clinical research programsto participate in the development of new therapeuticsto provide families with adapted reception, support and medical expertiseto train and inform in order to increase understanding and public awareness of these diseases.


The general structure of the Institute of Myology is under the medical and scientific direction of Dr Thomas Voit. AFM coordinates the structure and appoints Stéphane Roques, the Secretary- General. Directly attached to AFM’s general management, the Institute of Myology is subjected to a separate budget presentation at AFM’s Board of Directors. Apart from its coordinating and teaching activities, the Institute is engaged in 5 main areas of activities:

  • UMR 787 - Group Myology
  • Clinical Unit of Neuromuscular Pathology
  • Laboratory of Neuromuscular Physiology
  • Nuclear Magnetic Resonance Laboratory (NMR)
  • UMR 974 - Therapies of the disorders of striated muscle
  • Neuromuscular Morphology Unit.



Pierre Carlier Pierre Carlier

Dr Pierre Carlier is a leading specialist in magnetic resonance imaging and spectroscopy of muscle with a particular interest in its development as a quantitative outcome measure.

More Info


Thomas Voit Thomas Voit

Thomas currently holds the positions of Professor of Pediatrics (Professeurs des Universités –Praticien Hospitalier), Université Pierre et Marie Curie Paris VI, Scientific and Medical Director, Institut de Myologie, Groupe Hospitalier de la Pitié-Salpêtrière, Paris and Director, Mixed Research Unit UMR_S 974 UPMC-INSERM-CNRS-AIM.

More Info


Laurent Servais Laurent Servais

Graduated from Louvain Medical School (Brussels, Belgium) in 1999. PhD in Neuroscience (cerebellar electrophysiology in alert living mice) in 2005 from Free University of Brussels, Belgium. Child Neurologist in 2006, Free University of Brussels. Resident in Child neurology in Robert Debré Hospital, Paris, until 2008. Child Neurologist at the Institut de Myologie since November 2008.

More Info


Jean-Yves Hogrel Jean-Yves Hogrel

JY Hogrel is director of the Laboratory of Neuromuscular Physiology and Evaluation at the Institute of Myology.

More Info

Call + 33 1 42 16 58 74


Gisèle Bonne Gisèle Bonne

Gisèle identified the first mutations in the LMNA gene encoding the lamins A/C, to be responsible for the aurosomal dominant forms of Emery-Driefuss muscular dystrophy.

More Info


Rafael  de Cid Rafael de Cid

Rafael has developed a scientific career on the genomic analysis of human complex disorders.

More Info


Pascale Richard Pascale Richard

Pascale is a Medical Biologist, with a specialization in Molecular Genetics and after her PhD, was recruited at Pitié Salpêtrière to develop a diagnosis lab for cardiomyopathies. Then, she developped other neuromuscular disorders associated or not with a cardiomyopathy.

More Info


Stéphane Roques Stéphane Roques

In January 2009, Stéphane Roques became Secretary General of Généthon - the AFM's research arm, which is seeking to demonstrate the efficacy of gene therapy for rare diseases in general and neuromuscular diseases in particular.

More Info